Summary Bone markers may be useful to monitor response to treatment withdrawal in osteoporosis. We used two criteria for investigating the change in BTMs after withdrawal of bisphosphonate treatment. A larger increase in BTMs was associated with greater bone loss. Bone markers may be useful in monitoring of patients taking a pause from treatment. Introduction Measurement of bone turnover markers (BTMs) may be useful to monitor offset of treatment with bisphosphonates (BP) in osteoporosis. We assessed the effect of withdrawal of BP treatment by comparing the changes in BTMs and total hip (TH) bone density (BMD). Methods We studied postmenopausal osteoporotic women who had completed a randomised study of three oral BPs. After 2 years of treatment, participants with BMD T-score > − 2.5 and in whom it was considered clinically appropriate to discontinue treatment, were invited to participate in a further 2-year observational study. Biochemical response was assessed using BTMs (CTX and PINP) with offset being defined by two criteria: (1) an increase greater than the least significant change (LSC) and (2) an increase above the reference mean value. Results Fifty women completed the study. At 48 weeks after stopping BPs, CTX was greater than the LSC for 66% of women and PINP 72%; CTX was above the reference mean for 64% of women and PINP 42%. The decrease in THBMD was greater for women with the largest increase in BTM compared to those with continued suppression (mean difference for CTX was − 2.98%, 95%CI − 4.75 to − 1.22, P < 0.001, PINP − 2.25%, 95% CI − 4.46 to − 0.032, P = 0.046). Conclusion The measurement of BTM after withdrawal of BPs is potentially useful to evaluate patients that are taking a pause from treatment. An increase in BTMs more than the LSC and/or reference mean reflects loss of treatment effect and identifies patients that are likely to have a decrease in BMD. Such changes could provide an indication for reintroduction of treatment.
Introduction
Oral bisphosphonates (BPs) are widely used for the treatment of postmenopausal osteoporosis [1] . The beneficial effects may persist after treatment is withdrawn due to the retention of BPs in bone [2] [3] [4] , and it has been suggested that patients who are not at high risk of fracture may be considered for a pause in BP treatment [5] . When bisphosphonate treatment is interrupted, it is important to periodically review the patient to monitor for indications for recommending treatment. Clinical assessment usually includes measurements of BMD, but BTMs may be a useful adjunct for management [6] . Indeed, the International Osteoporosis Foundation (IOF) and International Federation of Clinical Chemistry (IFCC) have recommended the use of reference standard BTMs [7, 8] , which have been shown to decrease significantly after the Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00198-018-04823-5) contains supplementary material, which is available to authorized users. commencement of anti-resorptive therapies as a means to identify a response to treatment; the corollary suggests that it would be reasonable to consider that an increase in BTMs after treatment has been stopped may be useful to monitor the offset of effect in patients [9] . Certainly, when BP treatment is withdrawn there is an increase in the bone turnover markers (BTMs) and a decrease in the bone mineral density (BMD) [10, 11] , but little is known about their utility in clinical management.
We have previously reported the changes in BTM and BMD in a randomised trial of three oral BPs during and after withdrawal of treatment [12] [13] [14] . The criteria to define a clinically meaningful change or response in BTMs are not standardised, but two approaches can be used; firstly, a response can be assumed if the BTM changes from baseline by an amount that is greater than the least significant change (LSC), or the value on treatment can be compared to the reference interval, with response constituting a value that lies below the reference mean (for healthy young women) [7] . Similar approaches might be taken to define offset of the effect of treatment. In this analysis, we have investigated the relationship between changes in BTMs and BMD following the withdrawal of BP treatment to see if this could provide clinically applicable information for clinicians managing individual patients.
Methods

Study design
The study comprised a 2-year, open-label, parallel, randomised controlled intervention trial of three oral BPs (TRIO study) [12, 13] . At the end of the treatment study, eligible participants were invited to participate in an observational extension study for a further 2 years with no treatment (TRIO offset study) [14] .
Study population
The TRIO study recruited women with postmenopausal osteoporosis defined by dual-energy X-ray absorptiometry (DXA) at the lumbar spine or proximal femur as (i) a BMD T-score < −2.5 or (ii) a BMD T-score < − 1.0 plus a prevalent nontraumatic fracture. The recruitment details have been described previously [12] . Participants were randomised to receive one of the three oral BPs at the licensed dose for 2 years: (i) ibandronate (Bonviva, Roche, 150 mg), (ii) alendronate (Fosamax, Merck, 70 mg) or (iii) risedronate (Actonel, Warner-Chilcott, 35 mg) [12] and also received calcium carbonate 3 g (1200 mg elemental calcium) and cholecalciferol 20 μg (800 IU) per day (Adcal D3, ProStrakan), initiated 1 week before the commencement of treatment. The study, approved by the Sheffield Research Ethics Committee and the Medicines and Healthcare Products Regulatory Agency (MHRA), was carried out in accordance with the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice (ICH GCP) guidelines. Written informed consent was obtained for all participants. At the end of the 2-year treatment study, women with hip BMD T-score > − 2.5 and in whom it was considered clinically appropriate to pause treatment (n = 57) were invited to participate in a further 2-year observational study. The criteria for the invitation and subsequent inclusion in this TRIO Offset study have been published [14] .
Study outcomes and assessments
The total study was conducted over 192 weeks with visits at baseline one (week − 1), baseline two (week 0, randomisation and commencement of BP), then at 12, 48 and 96 weeks (TRIO study), then after the withdrawal of BP at 24, 48, 72 and 96 weeks (TRIO offset study). Fasting blood was collected (left to clot for 30 min, centrifuged at 2500g for 10 min) and stored at − 80°C until analysis. The C-telopeptide of type I collagen (CTX) and intact pro-collagen I N-propeptide (PINP) were measured using the IDS-iSYS (Immunodiagnostic Systems, Boldon, UK), inter-assay CV 4.4 and 4.5% respectively.
BMD (g/cm 2 ) of the total hip (TH) was measured by DXA (Discovery A densitometer, Hologic Inc., Bedford, MA) at baseline and weeks 12 and 96 on treatment then at week 48 and 96 off treatment (visit window +2 weeks).
Definition of BTM offset
The sample size for the TRIO offset study was constrained by the proportion of eligible patients from the original TRIO study [14] . Change in BTMs after withdrawal of treatment was classified according to two criteria, namely increases greater than the LSC and values rising to above the reference mean.
LSC
The least significant change (LSC) was calculated using measurements from the 12-and 13-week visits of the treatment group (n = 147) as follows:
Where SD RMS is the root-mean-square standard deviation calculated from the data, and Z′ is equal to 1.96 for 95% confidence level. Participants in whom the 48-week BTM measurement in the TRIO offset study showed increases greater than the LSC from the baseline value at an entry to the TRIO offset study was defined as having treatment offset. The LSC for PINP was 10 μg/L, while for CTX the LSC was 160 ng/L.
Reference mean
The reference mean value was calculated from 20 premenopausal women (geometric mean, 95% CI) who had participated as controls in the TRIO study. Participants in whom the BTM measurement at 48 weeks in the TRIO offset study lay above the premenopausal mean were defined as having treatment offset. The premenopausal means for PINP and CTX were 35 μg/L and 240 ng/L respectively.
Statistical analysis
Changes in TH BMD, from the start of the TRIO Offset study, are presented as least square mean percentage changes with two-sided 95% CI. The change in TH BMD after withdrawal of BP was compared by analysis of covariance (ANCOVA) with Bonferroni correction, adjusted for THBMD at baseline (end of treatment), in three groups for each of the BTMs; those showing offset by both a greater than LSC increase and a value lying above the threshold mean offset, those showing partial offset by only one of these criteria, and finally those showing neither of these criteria (no offset 
Results
Baseline characteristics
From the original TRIO study, 94 participants were assessed for eligibility and 59 consented to continue into the TRIO offset study, with two subsequently withdrawing before the start of the study. The baseline characteristics of those that entered the TRIO offset study compared to those who did not participate have been published previously [14] . In summary, at the TRIO baseline, the participants in the TRIO offset study (n = 57) were similar to all the participants in the TRIO study in terms of mean age (66.6 vs. 65.9 years, P = 0.67) and mean BMI (26.1 vs 25.1 kg/m 2 , P = 0.97) but, given the selection criteria for the Offset study, had higher TH BMD at both TRIO baseline (T-score − 1.14 vs − 1.70, P = 0.006) and at the end of TRIO (T-score − 0.9 vs − 1.6, P = 0.006). Of the 57 women recruited from the TRIO study, 18 had been allocated ibandronate, 21 alendronate and 18 risedronate [14] .
Bone turnover markers
Of the 57 women entering TRIO Offset, BTM data were available for 50 of them at 48 weeks after stopping BP. The increase in CTX was by more than the LSC for 33 women (66%) (Fig. 1a) and was above the reference mean for 32 women (64%) (Fig. 1b) changes in only one and 14 women (28%) in neither. The increase in PINP was by more than the LSC for 36 women (72%) (Fig. 1a) and was above the mean for 21 (42%) (Fig. 1b) 
Bone mineral density
The changes in BMD during treatment have been previously published [12] . We compared the change in TH BMD over 96 weeks off treatment in the three groups classified by BTM change after the withdrawal of treatment and at 48 weeks after stopping treatment (data were available for 49 women). At the end of the 2-year discontinuation period, only one participant had a BMD T-score of < − 2.5. Total hip BMD loss was significantly greater in those women showing BTM offset (a change in BTMs greater than the LSC and above the mean value at week 48 after stopping treatment) compared to those who only met one threshold (partial offset) or neither (Table 1 ). There was a significant difference in the TH BMD percentage change for those with offset by both criteria (LSC and reference mean) for CTX or PINP compared to those with neither criteria met (− 2.98%, P < 0.001, − 2.25%, P = 0.046, respectively) but no significant difference to those with neither criteria met, (either greater than LSC or the mean).
The participants with the greatest increase in BTMs at 48 weeks after stopping treatment had the largest decrease in TH BMD 96 weeks after stopping treatment CTX r = − 0.58 (95% CI − 0.74 to − 0.36) P < 0.001, PINP r = −0.41 (95% CI − 0.62 to − 0.14) P < 0.005.
Discussion
BTMs have been used in clinical research for many years but their uptake in clinical practice varies widely. One of the limitations to more widespread use is the relatively poor reproducibility of BTM, which can be addressed by adopting standardised sample handling and patient preparation procedures [15] . We assessed the change in BTM after the withdrawal of BP treatment using two criteria as suggested by the IOF and IFCC to monitor treatment of osteoporosis in postmenopausal women [7] . The values for CTX and PINP LSC and reference mean were comparable to those reported by Morris et al. [16] . Importantly, the offset of treatment effect using criteria for either the resorption marker CTX or the bone formation marker PINP was associated with more rapid bone loss at the hip over a 2-year period. Specifically, those women showing offset of the bone turnover suppression by changes in either marker at 48 weeks off treatment, particularly, when those changes were greater than the LSC, demonstrated greater decreases in hip BMD. These observations suggest that the monitoring of BTM at the earlier time point could prove useful in influencing follow-up and decisions to reintroduce treatment.
Another clinically important observation from our analysis is that women with higher BTM at baseline (prior to treatment) had a greater increase and return towards higher turnover during the offset period. Furthermore, the mean percentage decrease in TH BMD during the 2 years off treatment was greater in these women. These findings suggest that those women with high baseline BTM may require earlier assessment of offset to determine if there is an indication to restart treatment. The relationship between high baseline turnover and a subsequent return to relatively high turnover has been observed during denosumab treatment [17] . However, after the withdrawal of denosumab, there is a return to baseline followed by a transient increase in BTM above baseline associated with accelerated bone loss, whereas after BP withdrawal, BTM returned to baseline and bone loss is slower [18] .
It is important to note that the LSC method used absolute changes as used in clinical practice, rather than percentage changes, as the CTX value can be suppressed to zero with BP treatment so it would not be a suitable baseline for the calculation of percentage change during offset. Where a pretreatment baseline BTM measurement may not be available in clinical practice, a measurement at the end of treatment appears to be an appropriate baseline by which to assess the offset of the treatment effect. In the absence of a sample at the end of treatment, thus excluding the use of the LSC response, then values that lie above the premenopausal mean at 48 weeks can also identify apparent offset of effect, particularly when using CTX.
This study has a number of limitations. Firstly, the assay used for measurement of BTMs should be taken into account, as there are discrepancies between results from different manufacturers [15, 19] . Jorgensen et al. found significant disagreement between the IDS-iSYS and Roche Cobas assay for PINP and CTX. This will influence the reference intervals and it is recommended that patients should be monitored with the same assay [19] . The National Bone Health Alliance has recommended that standardised sample handling and patient preparation procedures are adopted to minimise variability [15] . It is important that the laboratory adheres to robust internal and external quality assurance programmes.
Furthermore, we acknowledge that the 2-year duration of BP treatment is not representative of the usual recommended clinical practice in postmenopausal osteoporosis, but many patients with poor compliance or persistence will withdraw from treatment in relatively short timeframes [20] . The effect of treatment may diminish at a different rate after withdrawal of treatment if the women were treated for a more standard 5 years with oral BP, but data from the oral risedronate study showed parallel rates of offset at 2 and 7 years [11] . We were not able to consider fracture rates, as the number of subjects is small, but the data on total hip BMD suggest that the observed offset is associated with potential clinical consequences. It is not clear that the use of BTMs in the setting of postmenopausal osteoporosis is translatable to offset in other forms of osteoporosis, particularly the causes of secondary osteoporosis such as glucocorticoid use. Finally, though allocation to BP was randomised, the criteria for the discontinuation of the treatment may have resulted in a non-random comparison amongst those who participated in the TRIO Offset study and does not include the women with more severe osteoporosis.
In conclusion, measurements of CTX and/or PINP appear useful in evaluating the offset of bone turnover suppression in patients that are taking a pause from BP treatment. An increase in BTM by more than LSC and/or change to greater than the reference mean predicts loss of BMD and by inference a possible increase in fracture risk. We propose the LSC as the optimal assessment of BTM offset with the comparison to the reference interval providing additional information to help clinical management of patients, particularly when there is no baseline BTM measurement available.
It would, therefore, be reasonable to use this as an indication to consider reintroduction of treatment if the individual is at high risk of fracture. Those with continued suppression of BTMs are likely to have a stable BMD and may remain off treatment with continued monitoring. 
